At the news
? BULLISHIMPACT 7/10 6-K filed Jun 12, 2026 at 06:02 ET
Ascendis Pharma announced 5-year (Week 266) data from its Phase 2 PaTH Forward Trial for TransCon PTH in hypoparathyroidism, showing sustained efficacy and safety. Key results include 82% responder rate on the multi-component endpoint, normalized serum calcium in 88% of patients, independence from active vitamin D in 96%, and maintained kidney function improvements. The data reinforces the drug's long-term profile, which is positive for the ongoing regulatory and commercial narrative.
- 82% of patients met the multi-component endpoint (normal serum calcium, no active vitamin D, <600 mg/day calcium) at Week 266.
- 88% of patients had normal albumin-adjusted serum calcium (mean 9.0 mg/dL).
- 96% achieved independence from active vitamin D; 95% from therapeutic calcium doses.
- Mean eGFR increased by 9.4 mL/min/1.73 m² from baseline to Week 266, sustained over 5 years.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access